Harnessing the power of dividing cardiomyocytes

Muralidhar, Shalini; Mahmoud, Ahmed I.; Canseco, Diana C.; Xiao, Feng; Sadek, Hesham A.

doi:10.5339/gcsp.2013.29

Cited by 9 publications

(13 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiomyocyte renewal rates in the postnatal heart are not definitively known [71]: Bergmann et al [72] estimated that ~50% of cardiomyocytes are renewed over a normal human lifespan but higher rates were reported in young adults by Mollova et al [73]. There is also evidence that in both neonatal and adult mammals, proliferation of pre-existing cardiomyocytes contributes to myocyte turnover [74] and that myocyte turnover can be enhanced by the ECM [43]. Further elucidation of the role that the ECM plays in regulating myocyte proliferation may provide a possible strategy to engineer scaffolds that recapitulate the endogenous myocardial regenerative capacity observed during early stages of heart development.…”

Section: Design Criteria For Engineered Cardiac Tissuesmentioning

confidence: 99%

Fibrous scaffolds for building hearts and heart parts

Capulli

MacQueen

Sheehy

et al. 2016

Advanced Drug Delivery Reviews

111

View full text Add to dashboard Cite

Extracellular matrix (ECM) structure and biochemistry provide cell-instructive cues that promote and regulate tissue growth, function, and repair. From a structural perspective, the ECM is a scaffold that guides the self-assembly of cells into distinct functional tissues. The ECM promotes the interaction between individual cells and between different cell types, and increases the strength and resilience of the tissue in mechanically dynamic environments. From a biochemical perspective, factors regulating cell-ECM adhesion have been described and diverse aspects of cell-ECM interactions in health and disease continue to be clarified. Natural ECMs therefore provide excellent design rules for tissue engineering scaffolds. The design of regenerative three-dimensional (3D) engineered scaffolds is informed by the target ECM structure, chemistry, and mechanics, to encourage cell infiltration and tissue genesis. This can be achieved using nanofibrous scaffolds composed of polymers that simultaneously recapitulate 3D ECM architecture, high-fidelity nanoscale topography, and bio-activity. Their high porosity, structural anisotropy, and bio-activity present unique advantages for engineering 3D anisotropic tissues. Here, we use the heart as a case study and examine the potential of ECM-inspired nanofibrous scaffolds for cardiac tissue engineering. We asked: Do we know enough to build a heart? To answer this question, we tabulated structural and functional properties of myocardial and valvular tissues for use as design criteria, reviewed nanofiber manufacturing platforms and assessed their capabilities to produce scaffolds that meet our design criteria. Our knowledge of the anatomy and physiology of the heart, as well as our ability to create synthetic ECM scaffolds have advanced to the point that valve replacement with nanofibrous scaffolds may be achieved in the short term, while myocardial repair requires further study in vitro and in vivo.

show abstract

Section: Design Criteria For Engineered Cardiac Tissuesmentioning

confidence: 99%

Fibrous scaffolds for building hearts and heart parts

Capulli

MacQueen

Sheehy

et al. 2016

Advanced Drug Delivery Reviews

111

View full text Add to dashboard Cite

show abstract

“…At birth, perinatal circulatory transition leads to increased oxygenation and separation of the pulmonary and the systemic circulation rapidly when the LV assumes the dominant pump function (1)(2)(3). Concomitant with morphological and functional modifications in the LV and RV (4,5), the neonatal cardiomyocytes (CMCs) undergo dramatic changes in morphology, respiration, metabolism, contractile function, and withdraw from the cell cycle (6)(7)(8)(9)(10)(11)(12)(13). It is known that distinct key transcription factors drive the chamber-specific gene networks during development (14,15).…”

Section: Introductionmentioning

confidence: 99%

Wnt11 regulates cardiac chamber development and disease during perinatal maturation

Touma¹,

Kang²,

Gao³

et al. 2017

JCI Insight

View full text Add to dashboard Cite

“…Indeed, we and others have shown, in vitro and in vivo, that viral delivery of E2F-1 to cultured rat neonatal and adult CM can overcome their cell cycle arrest imposed by p21 and p27 [58][59][60][61] . These results established the strategy that restoration of CM numbers after MI is a validated conceptual alternative to cell transplantation [62][63][64] .…”

Section: In Brief -Regulation Of Cardiomyocyte Proliferation By Cdk Imentioning

confidence: 79%

An emerging role for the Cdk-inhibitors p21Cip1/Waf1 and p27Kip1 as potential therapies for the treatment of cardiac hypertrophy

Stanley-Hasnain

Hauck

Billia

2018

Cardiovasc Regen Med

View full text Add to dashboard Cite

Heart failure is the leading cause of morbidity and mortality worldwide. Adult cardiomyocytes are post-mitotic cells that are substantially refractory to re-enter the cell cycle. This is exemplified by the absence of significant proliferative potential in differentiated cardiomyocytes. When exposed to aberrant growth stimuli, cardiomyocytes undergo maladaptive changes characterized by hypertrophic growth. The existing armamentarium of conventional pharmacological therapy can only slow the progression of the disease by alleviating the workload of the heart. Various agonist-and stress-induced extracellular signal transduction pathways could be target by novel agents for the treatment of pathological cardiac growth. Among these, the cyclin-dependent kinase inhibitors p21 and p27 have been recognized as potent inhibitors of apoptosis, growth and proliferation in cardiovascular disease. The role of the cell cycle factors p21 and p27 in the regulation of growth-associated processes in the heart, and their potential therapeutic implications are not immediately obvious, as it is the case in cardiovascular biology. In this review, we focus on the multiple functions of p21 and p27 in the regulation of hypertrophy, and briefly discuss pathways that play a critical role therein. All these selected studies attest an important role of p21 and p27 in the regulation of hypertrophy in isolated rat cardiomyocytes, and in various genetic murine models of heart failure. The available evidence suggests that therapeutic clinical approaches involving p21 and p27 have the potential to treat heart failure in patients.

show abstract

Harnessing the power of dividing cardiomyocytes

Cited by 9 publications

References 74 publications

Fibrous scaffolds for building hearts and heart parts

Fibrous scaffolds for building hearts and heart parts

Wnt11 regulates cardiac chamber development and disease during perinatal maturation

An emerging role for the Cdk-inhibitors p21Cip1/Waf1 and p27Kip1 as potential therapies for the treatment of cardiac hypertrophy

Contact Info

Product

Resources

About